We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
Total approvals
Agencies
Regulatory bodies
Founded
2012
No trial phase data available
No trial data available
No approval data available
- ProQR Therapeutics is advancing its Axiomer™ RNA editing platform across liver and CNS programs, with its lead program AX-0810 for cholestatic diseases on track for CTA filing in Q2 2025. - The company expects up to four clinical data readouts in 2025-2026, including first clinical data for AX-0810 in Q4 2025, supported by a strong financial position of €149.4 million providing runway into mid-2027. - ProQR's strategic partnerships include a $3.9 billion collaboration with Eli Lilly and a partnership with the Rett Syndrome Research Trust, reinforcing its leadership in the emerging field of RNA editing therapeutics.
